Glioblastoma is an aggressive form of brain cancer with no cure, but a new OMRF discovery offers hope.
An OMRF discovery could potentially open the door for the first drug option to treat age-related muscle weakness and atrophy.
In 1968, doctors told Greg Kindell that he had acute myeloid leukemia and he had just six weeks to live. Now he’s been cancer-free for 50 years.
Oblato, Inc., has acquired all rights from OMRF to OKN-007, an investigational drug for the treatment of a deadly form of brain cancer.
The project will focus on comparing certain immune cells in patients with Sjögren’s to those of healthy controls.
As Mike Schuster nears the three-year anniversary of his diagnosis with glioblastoma, he’s already doubled the life expectancy for patients with the deadly cancer.